AMAG Pharmaceuticals Hires Financial Advisor as the Company Explores All Opportunities to Enhance Stockholder Value

AMAG Pharmaceuticals, Inc. AMAG today announced that it has hired Jefferies & Company, Inc. as a strategic advisor. Jefferies will assist the company in identifying and evaluating various strategies to enhance stockholder value and leverage AMAG's core assets – Feraheme® (ferumoxytol) Injection for Intravenous use, AMAG's commercial and drug development infrastructure, and the company's balance sheet, which had more than $250 million in cash and investments, and no debt, as of September 30, 2011. “We are committed to enhancing long-term value for AMAG's stockholders,” said Frank Thomas, interim president and chief executive officer of AMAG. “The Jefferies team will help us evaluate all means to create stockholder value and support us in determining the best path forward for AMAG. We will expeditiously complete this process, which will include a parallel review of a potential sale of the company and other strategic merger and acquisition transactions.”